809 Shares in argenex SE $ARGX Acquired by Quantitative Investment Management LLC

Key Points

• Quantitative Investment Management LLC acquired a new stake in argenex SE, purchasing 809 shares valued at approximately $478,000 in Q1.
• Argenex reported a quarterly earnings per share (EPS) of $3.74, exceeding analyst estimates by $0.90, alongside a net margin of 40.98% and revenue of $866.79 million.
• Research analysts have shown strong confidence in argenex, with multiple upgrades and a consensus price target of $757.88, indicating robust projected performance.

Quantitative Investment Management LLC purchased a new position in argenex SE (NASDAQ:ARGX - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 809 shares of the company's stock, valued at approximately $478,000.

A number of other hedge funds also recently bought and sold shares of ARGX. Dimensional Fund Advisors LP boosted its stake in argenex by 21.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 24,929 shares of the company's stock worth $15,332,000 after purchasing an additional 4,445 shares in the last quarter. Stifel Financial Corp boosted its stake in argenex by 6.8% in the 4th quarter. Stifel Financial Corp now owns 9,433 shares of the company's stock worth $5,801,000 after purchasing an additional 601 shares in the last quarter. MGO One Seven LLC bought a new position in argenex during the 4th quarter valued at about $323,000. Voya Investment Management LLC lifted its stake in argenex by 47.8% during the 4th quarter. Voya Investment Management LLC now owns 14,170 shares of the company's stock valued at $8,715,000 after acquiring an additional 4,585 shares during the period. Finally, Coldstream Capital Management Inc. bought a new position in argenex during the 4th quarter valued at about $205,000. Institutional investors own 60.32% of the company's stock.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Morgan Stanley upped their target price on shares of argenex from $700.00 to $766.00 and gave the company an "overweight" rating in a research note on Friday, August 1st. Robert W. Baird upgraded shares of argenex from a "neutral" rating to an "outperform" rating and set a $680.00 target price on the stock in a research note on Tuesday, May 13th. Piper Sandler upped their target price on shares of argenex from $750.00 to $820.00 and gave the company an "overweight" rating in a research note on Tuesday, August 26th. HC Wainwright upped their target price on shares of argenex from $720.00 to $774.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Finally, Wells Fargo & Company upped their target price on shares of argenex from $741.00 to $756.00 and gave the company an "overweight" rating in a research note on Thursday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating and twenty have assigned a Buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $766.50.

argenex Stock Performance

Shares of NASDAQ ARGX traded up $8.13 during midday trading on Friday, hitting $712.20. 353,562 shares of the company's stock traded hands, compared to its average volume of 379,007. argenex SE has a 1 year low of $510.05 and a 1 year high of $716.62. The stock has a market capitalization of $43.59 billion, a price-to-earnings ratio of 36.52, a price-to-earnings-growth ratio of 0.81 and a beta of 0.41. The firm has a fifty day moving average of $611.18 and a 200 day moving average of $599.12.

argenex (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported $3.74 EPS for the quarter, beating the consensus estimate of $2.84 by $0.90. argenex had a net margin of 40.98% and a return on equity of 21.06%. The firm had revenue of $866.79 million during the quarter, compared to analyst estimates of $776.82 million. On average, equities analysts anticipate that argenex SE will post 3.13 earnings per share for the current year.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.